NewTimeSpace – 19 Jan: Hong Kong healthcare names are deep in the red. WuXi Biologics, Hansoh Pharma and Kelun-Biotech lead the slump; at 15:41 CSOP Hang Seng Biotech ETF (03174.HK) is down almost 3%. (Source: Wind)

The ETF, issued by CSOP Asset Management and listed on HKEX, tracks the Hang Seng Biotech Index—an all-HK, high-beta basket of innovators, CXOs, vaccines and gene-therapy plays.

PharmaCube tallies 15 fresh out-licensing deals by domestic innovators in December alone, lifting China’s 2025 export value to US$135.7 bn—more than double the 2024 figure—and underscoring rising global respect for Chinese R&D.

PD-1-plus pipelines stay hot: RC-148, AK112 and SSGJ-707 all scored big-stage wins. AbbVie bagged RemeGen’s RC-148; Pfizer will kick off five Phase IIIs for 3SBio’s SSGJ-707 next year; Sunshine/CSPC and I-Mab unveiled new lines; Summit has filed an AK112 BLA in the U.S. and will explore AK112-plus-ADC combos with GSK.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.